A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

NCT ID: NCT06799026

Last Updated: 2025-09-02

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 25 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-01-31
• Study Completion Date: 2030-09-01

Brief Summary

This research is being done to determine if the combination of the Dendritic Cell (DC)/ Multiple Myeloma (MM) fusion vaccine with elranatamab is safe and effective in treating Relapsed or Refractory Multiple Myeloma (MM).

The names of the study drugs and vaccine involved in this study are:

• DC/MM fusion vaccine (a personalized cancer vaccine in which harvested participant tumor cells are fused with harvested participant dendritic blood cells)
• Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) (a type of growth factor)
• Elranatamab (a type of T-cell engager antibody)

Detailed Description

This is a phase 1 study to evaluate the feasibility, safety, clinical and immune effects of DC/MM fusion vaccine in combination with Elranatamab in participants with relapsed/refractory multiple myeloma. The DC/MM fusion vaccine is an investigational agent that tries to help the immune system to recognize and fight against cancer cells. This vaccine is individualized for each participant using dendritic cells (type of immune cells) from each participant. GM-CSF contains a substance that helps make more white blood cells. This medication is being used to possibly increase the effectiveness of the DC/MM fusion vaccine.

The U.S. Food and Drug Administration (FDA) has not approved DC/MM fusion vaccine as a treatment for Relapsed or Refractory Multiple Myeloma.

The FDA has not approved GM-CSF as a treatment for Relapsed or Refractory Multiple Myeloma.

The FDA has approved elranatamab as a treatment option for Relapsed or Refractory Multiple Myeloma.

The research study procedures include screening for eligibility, in-clinic visits, blood tests, urine tests, study drug subcutaneous (under the skin) injections, Computerized Tomography (CT) scans, Magnetic Resonance Imaging (MRI) scans, or Positron Emission (PET) scans, and bone marrow biopsies and aspirations (or collections).

Participants will receive study treatment for up to 12 cycles (28-day cycles) and will be followed for up to 5 years.

It is expected that about 25 people will take part in this research study.

Pfizer is funding this research study by providing one of the study drugs, Elranatamab.

Conditions

Multiple Myeloma; Relapse Multiple Myeloma; Refractory Multiple Myeloma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Elranatamab + DC/MM Vaccine + GM-CSF

• Baseline visit and assessments
• Leukapheresis
• Cycle 1 (28-day cycle):

--Days 1, 8, 15, and 22: Predetermined dose of Elranatamab 1x daily

• Cycle 2 (28-day cycle):

--Days 1, 8, 15, and 22: Predetermined dose of Elranatamab 1x daily

• Cycles 3 through 5 (28-day cycles):

• Bone marrow biopsy/aspiration prior to first DC/MM fusion vaccine
• Days 1, 8, 15, and 22: Predetermined dose of Elranatamab 1x daily
• Day 8: Predetermined doses of DC/MM fusion vaccine 1x daily and GM-CSF 1x daily (GM-CSF for days 9 through 11 are self-administered)
• Cycle 6 (28-day cycle):

• Bone marrow biopsy/aspiration on Cycles 6, 9, and 12
• Days 1, 8, 15, and 22: Predetermined dose of Elranatamab 1x daily
• Cycle 7 through 12 (28-day cycles):

• Cycle 7 Day 1 only: Bone marrow biopsy/aspiration
• Days 1 and 15: Predetermined dose of Elranatamab 1x daily
• After end of treatment, bone marrow biopsy/aspiration at months 1, 3, and 6
• 6 month follow up visit
• Long term follow up 5 years

Group Type: EXPERIMENTAL

Elranatamab

Intervention Type: DRUG

Bispecific T-cell engager antibody, 1.9 and 1.1 mL vials, via subcutaneous (under the skin) injection per protocol.

GM-CSF

Intervention Type: BIOLOGICAL

Granulocyte-Macrophage Colony-Stimulating Factor, via subcutaneous (under the skin) injection per protocol.

DC/MM Fusion Vaccine

Intervention Type: BIOLOGICAL

Dendritic Cell and tumor fusion vaccine, via subcutaneous (under the skin) injection per protocol.

Interventions

Elranatamab

Bispecific T-cell engager antibody, 1.9 and 1.1 mL vials, via subcutaneous (under the skin) injection per protocol.

Intervention Type: DRUG

GM-CSF

Granulocyte-Macrophage Colony-Stimulating Factor, via subcutaneous (under the skin) injection per protocol.

Intervention Type: BIOLOGICAL

DC/MM Fusion Vaccine

Dendritic Cell and tumor fusion vaccine, via subcutaneous (under the skin) injection per protocol.

Intervention Type: BIOLOGICAL

Other Intervention Names

PF-06863135; Elranatamab-bcmm; Elrexfio; Granulocyte-Macrophage Colony-Stimulating Factor; Dendritic Cell/Tumor Fusion Vaccine

Eligibility Criteria

Inclusion Criteria

• Participants must have an established diagnosis of multiple myeloma
• Participant must have multiple myeloma and have relapsed following or are refractory to proteasome inhibitors, IMiDs and anti-CD38 mAb therapy
• Participants must have at least 3 prior lines of therapy
• Participants must be ≥18 years of age
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
• Participants must have > 20% plasma cells in the bone marrow core or aspirate differential <30 days prior to enrollment.
• ANC > 1K/uL; Platelets > 50 K/uL without transfusional support
• Participants must have adequate organ function as defined below:

• Total bilirubin ≤1.5 x institutional upper limit of normal
• AST ≤ 3 x institutional upper limit of normal
• ALT ≤ 3 x institutional upper limit of normal
• Creatinine clearance ≥ 40 mL/min for participants with creatinine levels above institutional normal
• The effects of DC/MM fusion vaccine on the developing human fetus are unknown. For this reason, women and men of child-bearing potential must agree to use adequate contraception (hormonal or barrier methods of birth control or abstinence) prior to study enrollment and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner are participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of treatment.
• Ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria

• Patients who are receiving any other investigational agents.
• Patients with purely non-secretory MM [absence of a monoclonal protein (M protein) in serum as measured by electrophoresis and immunofixation and the absence of Bence- Jones protein in the urine defined by use of conventional electrophoresis and immunofixation techniques and the absence of involved serum free light chain >100 mg/L]. Patients with light chain MM detected in the serum by free light chain assay are eligible.
• Patients with Plasma Cell Leukemia
• Because of compromised cellular immunity, patients who have a known human immunodeficiency virus (HIV), active hepatitis C virus (HCV) or active hepatitis B virus (HBV).
• Myocardial infarction within 6 months prior to enrollment or New York Heart Association (NYHA) Class III or IV heart failure (see Appendix H), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at screening will be documented by the investigator as not medically relevant.
• Active and clinically significant autoimmune or inflammatory disorder requiring active treatment
• Individuals with a history of a different malignancy are ineligible except for the following circumstances. Note: Individuals with a history of other malignancies are eligible if they have been disease-free for at least 2 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: non- invasive cancer (such as, any in situ cancers) and basal cell or squamous cell carcinoma of the skin.
• Female patients who are pregnant (positive β-HCG) or breastfeeding
• Prior organ transplant requiring immunosuppressive therapy.
• Patients who previously received PD-1 antibody and have experienced toxicities resulting in treatment discontinuation.
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• History of GBS or GBS variants, or history of any Grade ≥3 peripheral motor polyneuropathy.

Eligibility Criteria Prior to Vaccination with DC/MM fusions

• Resolution of all elranatamab related ≥ grade 3 or higher toxicities to grade 1 or baseline. Isolated laboratory abnormalities that are not considered to be clinically significant are not exclusionary.
• Successful production of at least 2 vaccines with a minimum of 1 x 106 fusion cells per vaccine
• Absence of disease progression following 2 cycles of elranatamab therapy
• ECOG performance status ≤ 2

Participants must have adequate organ function as defined below:

• Total bilirubin ≤ 1.5 x institutional upper limit of normal
• AST ≤ 3 x institutional upper limit of normal
• ALT ≤ 3 x institutional upper limit of normal
• ANC > 1K/uL; Platelets > 50 K/uL without transfusional support
• Creatinine clearance ≥ 40 mL/min for participants with creatinine levels above institutional normal

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Pfizer

INDUSTRY

Sponsor Role: collaborator

David Avigan

OTHER

Sponsor Role: lead

Responsible Party

David Avigan

Sponsor Investigator

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

David Avigan, MD

Role: PRINCIPAL_INVESTIGATOR

Beth Israel Deaconess Medical Center

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Site Status: RECRUITING

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

Site Status: NOT_YET_RECRUITING

Countries

United States

Central Contacts

David Avigan, MD

Role: CONTACT

davigan@bidmc.harvard.edu

617-667-9920

Emma Logan, MSN

Role: CONTACT

eklogan@bidmc.harvard.edu

617-667-9920

Facility Contacts

David Avigan, MD

Role: primary

davigan@bidmc.harvard.edu

617-667-9920

Emma Logan, MSN

Role: backup

eklogan@bidmc.harvard.edu

617667-9920 ext. Logan

David Avigan, MD

Role: primary

davigan@bidmc.harvard.edu

617-667-9920

Other Identifiers

24-439

Identifier Type: -

Identifier Source: org_study_id